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1)esl)itr atlcanws i n  oi)vrativt, tec*lniic~ues ant1 sltill, ant1 
1)artly e\ac.erl)atrtl I)! 1)atients lwing referre(1 ior rar- 
tliac surgical procetlures at atlc aricetl stagrs of tlisease, 
postoperative centricular tl! sfmication is not uncom- 
monly seen. In  ul) to 10% of high-risk patients in whom 
carc1iol)"lmonary I n  pass is used ~ an  intra-aortic hal- 
loon pun111 (L4BP) is required for  separation from 
1)jpass. ' Because an IABP will augment cardiac out1)ut 
1)) only 10% to 15%- some patients will require more 
significant ventricular support such  as froin left (L\:ADs) 
antl right ventricular assist tlecices (RVADs). Further- 
more. excessiv e doses of inotropes can he avoitled. 
In  199%. the Food and Drug Administration (FDA) 
approved the ABIOMED (ABIOMED, Inc, Danvers, 
MA) BVS 5000 Biventricular Support Sjstem for post- 
carcliotoiny ventricular dysfunction.' The device was 
designed to provide pulsatile left weiitriculai-. right 
ventricular, o r  hiventricular support (BVS) with mini- 
mal cost antl ininin~al complexity of implantation and 
operation. ' The system consists of single-use blood 
pumps that a re  actuated b y  a pneumatic drive console. 
Each pump is attached to an  intravenous pole a t  the 
liedside. allowing its height relative to the atrium to lie 
adjusted. This facilitates gravitational control of pump 
filling. 
Each blood pump (Fig I) allows unidirectional flow of 
Hood into two chambers, a filling (atrial) chamber and 
a pumping (ventricular) chamber. Two tri-leaflet Angio- 
flex (ABIOMED, Inc, Danvers, MA) polyurethane valves 
a re  seamlessly interposed on either side of the ventricu- 
lar  chamber, allowing only for unidirectional flow. Each 
chamber contains a smooth-surfaced polyurethane hlad- 
der. As the ventricular bladder fills, air surrounding it 
is displaced to the console. The console's electronics 
sense filling of the pumping chainher and return pressur- 
ized air  to the outside of the chamber, causing ejection 
of the blood. The system is modulated to pump at a rate 
that allows for 70 to 80 mllejection and flows of up  to 
6 Llmin. During operation, pump filling is determined 
b y  the position of the blood pump relative to the level of 
the atrium. The pump output can lie manually de- 
creased during weaning, hut otherwise, it is controlled 
automatically. 
Since its approval for use. the intlication~ for the 
device have expanded to include use in selected patients 
who suffer significant cardiac dysfunction. wlitw recov- 
ery is likely such as in postcardiotomy shocli. failed 
cardiac transplantation, '.' right heart failure a f te r  
LC placemvntnf' acutts in! oc-artlial infarction with 
4 iock .  antl viral niyocarclitis. 6 It h a <  also 1)een succeis- 
ful ly  nsetl in treatment of patients with intractable 
ventricular tachycardiax and rhetuiiiatic pricartlitiz." 
Even wheii cardiac recovery is tlouhtful, the device may 
he nsed as a IiritIge-to-transplantation. "'.' ' Patients 
with pstcar t l iotomj failure stJlectetl for BVS should 
have liatl a technically successful operation hut fail to 
tolerate separation from carcliol)uliiionar! bypass as 
evidenced h y  a cardiac index Ijelow 8.0 Llminlm', 
central venom pr lire and left atrial pressure greater 
than 18 niin Hg, and SVOL (mixed venous oxygen 
saturation) less than 55% despite hemoglo1)in correc- 
tion antl significant inotropic support. Patients should 
also 1)e of a reasonable physiological age and have a 
body surface area greater than 1.3 in'. Ideally, they 
should he recognized as candidates quiclily, certainly 
well within 6 hours of initiation of cardiopulmonary 
hypass. Whether o r  not an  IAPB is used, transesopha- 
geal echocartliography can lie quite useful in determin- 
ing the ventricular function and in assessing a patient's 
need for ventricular assistance. More importantly, assess- 
ment for a patent foramen ovale should be performed. 
This would require closure to prevent right-to-left 
shunting of desaturated blood with left-sided support. 
Contraindications to the use of the BVS 5000 may 
include renal failure, severe liver disease, metastatic 
cancer, uncontrolled sepsis, interstitial pulmonary hem- 
orrhage with inadequate pulmonary function, severe 
hemolysis. uncontrollable hemorrhage, and significant 
central nervous system injury. 
The device is relatively straightforward to implant 
and requires minimal I~edside adjustment. Several can- 
nulae a re  available for  use in insertion of the BVS 5000 
device (see 1 in the Surgical Technique (ST) section). 
All have an  attached Dacron (E.I. DuPont de Nemoiirs 
and Co, Inc, Wilmington, DE) velour sleeve, which is to 
be positioned at  the exit site from the skin in order to 
improve hemostasis and encourage tissue adherence 
and ingrowth. There a re  two atrial cannulae: a mal- 
leable tip 36F antl a right-angled 4ZF cannula with a 
lighthouse tip. The arterial cannula is a 42F cannula 
with a 14-mm elastomer-coated Dacron graft distally. 
Plastic hullet tips a re  provided to allow passage of the 
cannulae out of the pericartlial cavity through subcuta- 
neous tunnels and the skin (see 1 in ST). There a re  
three options for left atrial cannulation: through the 
dome of the left atrium hetween the superior vrna cava 

























Fig I. Cross-section of the BVS 5000 hlootl pimp dnriiig cliastolir 
(left) and systolic (right) puinping phases. (Reprinted with permission 
from ABIOMED. Inc, Damers, MA.) 
and the aorta (see 4 in ST), on the right side of the heart 
behind the interatrial (Waterston’s) groove (see 5 in 
ST), and through the left atrial appendage. A fourth 
“atrial” cannulation site is through the apex of the left 
ventricle (see 6 in ST). This site may be superior for 
patients with mechanical mitral valve prostheses be- 
came it allows good blood flow across the valve, 
reducing the risk of stasis-related thrombosis that may 
occur with cannulation at the other sites. 
Right atrial cannulation is performed through one of 
two sites: through the right mid-free wall (see 7 in ST) 
and through the right atrial appendage. In patients 
failing to wean from cardinpulmonary bypass after 
coronary artery bypass. the right atrial appendage is 
ordinarily occupied b y  a two-stage venous cannula, 
thus making the free wall an ohvious choice for right 
atrial cannulation in this circumstance. Nevertheless, 
the free wall site is superior to the atrial appendage no 
matter the position of the venous cannula because it 
allows better drainage of the venous return. Suboptimal 
flow in a cannula placed through the right atrial 
appendage may be caused by obstruction of the cannula 
tip due to collapse of the appendage around the intake 
orifices. Placement of the arterial cannulae (see 9 in 
ST) requires sufficient room on the ascending aorta and 
the pulmonary artery for placement of a 14-mm Dacron 
graft in an end-to-side fashion. If vein grafts are in 
place on the ascending aorta, they should be avoided, 
or, if necessary, moved. Although the atrial cannulae 
can be pulled through their subcutaneous tunnels 
before insertion into the heart, the arterial cannulae 
are best anastomosed to their perspective vessels before 
tunneling. This allows mobility of the graft in order to 
check the anastornotic sight for hemostasis, especially at 
the heel. When satisfactory anastomotic hemostasis is 
verified, the arterial cannulae are then advanced 
through their subcutaneous tunnels, confirining proper 
IIositioning and avoiding kinking. 
SURGICAL TECHNIQUE 
1 (A) Several cannulae are available for placement: (a) a 42F Dacron-cuffed arterial cannula; (b) 
a 42F right-angled atrial cannula with lighthouse tip; and (c) a 36F atrial c.annula with mallealde 
end. (B) After deciding on optimal orientation of the cannulae. suhcostal skin incision3 to 
ac~comniodate the cannulae a re  made. For this, an  ellipse of skin 70% of the diameter of the cannula 
is made. Retracting this opening with sliiii hooks a l low creation of a hemostatic tunnel and a snug 
liut liollc(~iistri(,tiii~ fascia1 clefect. ,.1 plastic h d e t  tip is attached to each cannula. The cannula is 
then drawn froni the pvricardial i p a w  throiigh the subcutaneous tunnel with a lira 
the completion of the procetlnre, each cannula is sec*ured to the skin with large stitches. 
\ \  
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3 (4) There are three marks on the end of each atrial cannula at 1.2,  aiitl 3 cm from the most 
proximal inflow orifice. These are useful for cannula positioning. 
(B) The cannula is inserted through the purse string to a point beyond the second mark and is 
gently rotated to an optiinal position. During this placement. the heayt is allowed to fill, and 
during left atrial cannulation, a Valsalva maneuver is performed b y  the anesthesiologist. This 
allows filling of the cannula and prevents air ingress to the heart. The filled cannula is then 
clamped distally. 
(C) The tourniquets are then tightened around the cannula. The tourniciuets will reniain in 
place until decannulation; therefore, any of many ingenious measures should lie taken to 
prevent the purse-string sutures from loosening. We tie each suture o9er a large button. leaving 
enough suture length within the tourniquet to allow it to be rasil! t i c d  when the cannula is 
re1novetl. 
(D) The tourniquets are then secured to the cannula with two heavy silk ligatures in order to 
prevent dislodgment or rotation of the cannula. 
A 'I 
4 If left ventricular support or BVS is required, the left atrial cannula is inserted first. The preferred 
cannulation site at our institution, and at those of others,'l is through the dome of the left atrium. 
(4) Exposure of thi3 site is usually easily provided through leftward retraction of the aorta ancl rightward 
retraction of the superior vena cava. (B) The cannula is passed through a subcutaneous tunnel, and the 
proxiiiial tip is inserted into the left atrium through an atriotoiny within a double purse-string suture as 
t1escril)etl in 2 aiitl 3. During insertion, the heart is filled. and a Valsalva maneuver is perfolmetl. allowing 
the cannda to fa. There are a nunher of advantages to l i 5 q  tllii 5ite. For both normal ancl small left atria, 
exposure and cannulation of the clome ii ea5ier than at other sites. Little, if any, m a ~ p d a t i o n  of the heart is recpired 
for exposnrc of this site. Bleeding from the left atrial dome while cantidated or upon decamidation is more easily 
rtmtrolled than at other left atrial cannulatioil sitrs, A cxnntda plac.ed hehin(l the interatnal groovr may 1lak.r 
s ~ h p t i r n a l  flow or ma) un1)inge on the klte1-atl-d beptuni. retlucmg flow in the right ventricdar a 
device. Repositioning of the cannula to the left atrial dome usually alleviates these problems. Two situations 
in which 1i5ing thr. left atrial tlotiie api)i-oach may not he pnsdlle are: (1)  if an oversized aorta is I,resent. or 
( 2 )  when grafts from the aorta to  the right rol-onary systrtli w d  1~ ~(~1nPI-oIni~ecl Ily this ~*:innrila loc.ation. 
J 
5 What was previously the standard site for left atrial cannulation was Iiehind the 
interatrial groove hetween the right superior and inferior pulmonary veins. The technique 
is as tlescribed in 2 and 3. The caiiuula size precludes use of one of the pulmonary veins for 
its insertion. There are downfalls to this cannulation site. Manipulation of the heart is 
required for its exposure. Dissection of the interatrial groove may he recpired. especially in 
order to gain exposure to a small left atrium. Control of bleeding at this site is more difficult 
and requires much more manipulation of the heart than for a site in the left atrial dome. 
Because of the amount of manipulation of the heart, cardiopulmonary bypass is usually 
required in order to safely expose bleeding sites around a cannula at the posterior 
interatrial groove site.13 Bypass is much less likely to be required in order to control 
bleeding from the left atrial dome cannulation site. In addition, the tip of the cannula, when 
placed through this site. could impinge on the interatrial septum. This would not only 
directly decrease LVAD flow from obstruction of the left atrial cannula, but it can also 
diminish RVAD. and siihsequently LVAD, flow bec:ause of ohstrnction by the septum of 
RVAD return. This site. however, is preferred over the left atrial appendage heranse the 
al>i>entlage is composed of tissue that is inore fragile, provides less relia1,lr left atrial 
drainage. and can be quite trdious to arcess in most patients. 
A 
6 (A) An approach to left atrial callnulation that is gaining popularity is caiuiilatioii of 
the left ventricle through the apex. 111 this approach, two pledgeted 2-0 purse-string sutores 
are placed in the same fashion as described in 2 and 3, to the left of the left anterior 
descending coronary artery near the left ventricular apex. The preferred site is not the 
actual left ventricular apex, hut a site on the anterolateral aspect of the apex. The preferred 
atrial caiinula in this technique is the 36F catheter with the malleable tip. Despite its smaller 
size. flows obtained should be cpite adequate. 
6 (continued) (B) After the distal cannula end is brought out through the skin, the 
proximal end is introduced into the left ventricle through a cruciate incision within 
the purse strings. The cannula is secured as previously described. In a patient without 
mitral stenosis, excellent decompression of the left atrium and left ventricle is 
accomplished. This site is certainly preferred over the left atrial appendage if access 
to the left atrial doine or  posterior intra-atrial groove is not available. As already 
stated, this site also allows good flow across a mitral valvular prosthesis, hopefully 
diminishing the risk of valve thrombosis secondary to stasis. 
7 Two right atrial cannulation sites are available: the free wall and the atrial appendage. 
RVAD inflow is usually superior with the caiinula placed in the right atrial free wall. 4 
two-stage venoiis cannula usually occupies the appendage iii patients already on cardiopul- 
monary bypass. A cannula placed through tlie right atrial appendage may become partially 
or totally ohstructd if the walls of the appendage collapse around the cannula tip. 
Regardless of the location. cannulation is accoinplishecl through the techniques in 2 and 3. 
If the patient has a two-stage venous cannula in position, it maj cause difficulty for 
cannulation if it is not repositioned. The tip of the two-stage cannula should be gently 
withdrawn from the inferior vena cava and advanced through the tricuspid valve into the 
right ventricle. After place~nrnt of the purse-stnng sutures in  the right atrial free wall, the 
RVAD atrial cannula is then advanced through the &in. The right atrium is allowed to fill, 
and the cannula is inserted into tlie atrium to a p i n t  pa5t the 2-cm mark. The cannula is 
then appropriately secured a i d  is I)acIifilled with I~l00d. 1 tul~ing clalnp is applied clistall) 
on the cannula. 
8 Before arterial cannulation. the cannula reqnires 
some preparation. This distal end of the arterial cannula 
consists of a coated Dacron graft. -Uthough ldeeding does 
not occur through its interstices, it can occur through 
needle holes at the anastomosis. There are various tech- 
niques to lessen this problem.14 We excise the Dacron graft 
from the cannilla and replace it with a 14-min Henia- 
shield (Meadox Medical Inc., Oakland. NJ) woven, double- 
velour vascular graft. This graft is sutured to the end of 
the cannula with a 4-0 polypropylene stitch on a small 
needle. A small cuff of the same graft, approximately 2 
cin in width. is then pnlled over this anastomosis in order 
to improve heniostasis at this site. We have had fewer 
hleeding problems from the anastomosis with this tech- 
nique. An aclcled advantage of the Hemashield graft is its 
pliability. This decreases the liltelihood of ltinlting a i d  
facilitates expo5nre when performing the anastomosis. 
9 The arterial cannillae are anastomosed to the ascending aorta and to the pilnionary artery. For aortic 
cannillation. any site on the ascending aorta can he used, but the anterolateral wall is the site usnally 
selected. The site shoilld he free of bypass grafts. Ifnecessary, the cannula can he placed more posterior or 
more tlistally on the aortic arch, but exposure and anastomosis at these sites can he quite dlfficdt. If 
necessary, a pi-o~i~iial location of a hypass graft can be changed. To complete its preparation, the hstal 
Dacron eiitl of the arterial cannula is cut at a 30" bevel. A partial occlusion clamp is applied longitucbially 
to the aorta. An aortotoiny of appropriate length is performed, and the Dacron portion of the cannula is 
anastoniosed to the aorta in an encl-to-side fashion with a 4-0 polyp-opylene stitch. Because bleeding from 
the heel of the anastomosis is difficult to correct, this site is buttressed with a separate pledgeted stitch. 
Some surgeons reinforre the entire anastomosis with a felt strip. The partial occlusion clamp is then 
removed, and the caimda is allowed to fill with blood. AU air buhhles are evacuated from the cannula, with 
special care taken to remove any air trapped along the Dacron cuff. The anastomosis is checked for 
hemostasis. Dc-airing of the cxaimda and checking the anastomosis for hemostasis is greatly facilitated by 
waiting to exteriorize the c:amiula after the anastomosis is perfornied. Once hemostasis, proper anastomotic 
orientation, and coniplete tleairing of the cannula are assured. the 1)nllet tip is attached to its end and the 
cannula is pillletl through its sihcostal sidjcntaneous tunnel. The 1dnonary artery anastomosis should be 
performed away from the Imhonary valve in order to keel' it fi-re from injury. A bevel, more steel) than 
3O0, may he requird for this anastomosis. A partial occlusion clamp is placed on the main p ihonary  
artery (or it ('an I)c Ijroximally snared). \vith cai-c talien to not injnre the pulmonary valve. As with 
plat-ement of the aortic cannuda. a longitut~inal arterioto~ny is performetl and the anastomosis is coiiipletecl. 
Positioning, checking for hemostasis, and air evacuation are again performed before the cannida is passed 
through its sid)costal tunnel. If direct canlidation of the plrnonary artery is not pssihle, as in patients 
ious s argeries an alteriiative arterial cmniidatioii 1)rocedui-e for the RV,iD can 1le 
pei-forined. .As desc~ril)rd in 2 and 3, a tIouI)le prse-strUig stitvh is placetl over the right venti-icudar outflow 
tract. Through this, the 36F atrial cannda is placed and cai-efillly advanced across the pulmonary valve 
into the pnhnonary artery. The cannula and its purse-string stitches are secured in the stantlard fashion. 
ABIOMED'S 
BVS System 5000 
I 
Left heart 
BVS p u m p  
10 While the cannulation is being performed. the BVS 5000 pumps and tubiag are primed and 
cleared of air. The cannulae are then connected to the appropriate atrial and arterial lines of the 
pump tubing without allowing air into the system. The pericardium is filled with warm saline 
solution, the patient is placed in a steep Trendelenburg position. and as the heart is filled, an 
assistant initiates flow in the device slowly with a foot pniiip. This allows a final check for air in the 
system. If any air is present, the lines are clamped and the system is again cleared of air. Ally sites of 
leakage around the atrial cannulae are corrected. The devices are secured at the bedside to an 
intravenous pole with their height 0 to 10 cin helow the atrium when the 42F atrial cannula is used. '4 
height of 4 to 14 ('m below the atrium is used for the 36F atrial cannula. The device is switched to the 
automatic position, the intravascular volume is expantled. and the patient is  weaned from 
cardiopulmonary 1 ) )  pass. Full reversal of heparinization with protamine sulfate and correction of 
any cwagulation al,noi-inalities with an) nec.es$ary ldootl products i5 then achietetl. (Reprinted with 
permission from ABIOMED. Inc. Danvers. MA.) 
Tie wram 
Smooth junction ' I  
Tubing connector 
1 1 With proper function of the device assured. completion 
of the connection of the cannulae to the ~~11111p tubing is 
performed by snugging the spc ia l  flared callnil~a restraint ctver 
the cannula-to-tubing connection site. Two tie wraps are placed 
to finally sectii-e the connection. The flared restraint compresses 
the cannula around the hlooci pnmp tubing. forming a junrtion 
that is smooth. This lessens the risk of thrombosis or throinboem- 
liolism that could occur from turbulence along a niore rough 
connection. The pumps and tubing are then surroundetl with 
special insulating jackets in order to lessen heat loss from the 
system. Two large mediastinal drains are placed, and the 
incision is closed. Intravenous antibiotics are continued for at 
least 3 days. (Reprinted with permission from ABIOMED. Inr, 
Danvers, MA; U.S. patent number 4.826-477.) 
Perioperatiw e Maiiageiiieiit 
Implantation procedure* for tlie B\ S ,5000 are rela- 
tivel! straightforward. R;laintenanre of t he  siipporte(I 
patient postoIierativerly is relatitiel> simple as well. 
During implantation of thr BVS 5000. the patient 
shoultl Ije i y  stemirall! 1iel)arinizetl. Cart1iol)ultiioi~ai.y 
hypass is usuall! initiated or continued for placement of 
tlie cannulae. In t rao~)era t i~  e transesol~hageal echocar- 
diography should he used to evaluate the patient for the 
presence of an atrial septa1 tlefect or of a patent 
foramen ovale. If surh a tlefect is fonntl, it should he 
closed hefore ini~ilantation of the device. When the 
cannulation is completed antl the tubing is shown to he 
free of air, the device is started. If BVS is ixsecl, the 
LVA4D is started before starting the RVL4D in orcler to 
decrease right ventricular afterload antl avoid inciting 
pulmonary edema. During BVS ? the LYtlD output 
should be kept at the same as or slightly higher than 
that of the RVAD. If pulmonary congestion is noted 
postoperatively, the LV4D flows can be iiicreasetl to as 
much as 0.5 to 1.0 Limin ahove that of the RV4D. antl 
this should improve pulmonary venous congestion. This 
can be accomplished by adjusting the height of the 
pumps at the bedside relative to the atria. The BVS 
5000 can be used for left ventricular support, right 
ventricular support, or BVS. The great majority of 
implantations have included left ventricular support. 
Predicting which patients will need RVAD support after 
LVAD implantation may be difficult. Reports suggest 
that 2 0 7 ~  to 6 0 7 ~  of patients who receive LVADs will 
require additional support from an RV-4D. l i . lh There 
are no absolute predictors for acute or delayed right 
ventricular failure. The placement or presence of an 
RVAD is not likely to increase perioperative morbidity 
or mortality, and in a patient who is destined to have 
delayed right ventricular failure after LVAD placement, 
it may certainly improve the outcome. Findings that 
would strongly suggest the initiation of RVAD as well as 
LVAD support include right ventricular injury or infarc- 
tion, perioperative elevation of pulmonary vascular 
resistance, elevation of the right atrial or central venous 
pressures above 20 mm of mercury, and right ventricu- 
lar distention with poor contractility visibly or by 
intraoperative transesophageal echocardiography. The 
heart should be observed for at least 30 minutes after 
the LVAD is started before it is decided that the right 
ventricle will not need support. 
Postoperative Heeding is the most com~iioii complica- 
tion after VAD placement. It occurs in up to 76% of 
patients, and as many as 2 0 7 ~  to 377r of patients will 
require nperative intervention to control the bleeding 
or it9 ronsequences, namely cardiac tamponade.'-' I' 
In order to diminish this problem, heparinization is 
fully reversed after implantation of the device. Any 
c~)a;iilation ahnornialities are full! correc~ttvl I)! tlelib - 
e n  of platelet<" l'lasma. or cr! oprrcipitate as neetltd. 
For tlir first 8 to 12 hour s  of tle\icr rise. no anticwag- 
dation i* required as long as  f lows  are greater than 
3 L/niin. After this. intravenous heparin is started a s  a 
tlrjlj \+itliout 1)olus. kee1)ing the a d \  attvl c*lotting tinit* 
( ACT) 1)etween 180 antl 200 seconds ant1 monitoring 
mrtliastinal drain oiitj)ut. T)urinp uraning off of the 
&\ice,  or if f lows  tlecreasr~ belo\+ 3 Limin. tlie 4CT is 
increased to SO0 seconds. Dnring use of the tle,icr, tlie 
patient'\ hematocrit is kel)t above 3 0 7 ~ ~  and the platelet 
count is kept almve 80.000. At tlie sign of cardiac 
tamponade (essentially, tlecreased TAD flows despite 
fluid challenges aiid adequate filling), the patient is 
returned to the operating room to explore the mediasti- 
nun1 for bleeding or for repo4tioning of the cannulae as 
necessary. Some centers simply close the skin with a 
rubber tlani or clear plastic in order to assess ant1 more 
easily explore for tamponade. We choose to close the 
sternum with three circumsternal stainless steel wires 
antl close the sl& as well. The potential advantages are: 
improved hemostasis hecause of tliminished sternal-edge 
bleeding, decreased heat loss from the patient, decreased 
risk of iufection, and improved respiratory dynamics, 
which allows for early extubation and mobilization. Pa- 
tients in whom sternal closure is performed suffer de- 
creased incidence of reoperation for bleeding. The patient 
shoulcl he extuliatetl as early as possible postoperatively. 
Intravenous inotropic support requirements should 
he markedly reduced with appropriate function of the 
VADs. The use of vasopressors or vasodilators may be 
required postoperatively in order to help modulate 
systemic vascular resistance or  pulmonary vascular 
resistance. Use of these medications, as well as appropriate 
intravascular volume expansion, should be used in 
order to keep the mean arterial blood pressure approxi- 
mately 60 mm Hg. If an IABP is in place before 
implanting the LVAD, it should be adjusted to trigger 
with the arterial pressure waveform as the pump ejects 
asynchronously to the cardiac rhythm. 
After 3 to 5 days of ventricular support, slow weaning 
off of the device should be attempted if it is believed that 
recovery of cardiac function has occurred. Over 90% of 
patients who can be weaned from BVS are weaned by 1 
week after initiation of the support. In  patients who 
receive BVS for postcarcliotomy ventricular failure and 
are not able to be weaned from support after 1 week, 
serious consideration for rartliac transplantation should 
be made, especially if these patients are transplant 
candidates hecause they are not likely to wean from 
BVS beyond this time. Recovery can he assessed h y  
noting ventricular ejection waves in the arterial tracing 
or by obtaining a transesophageal echocardiogram 
while the VAD flow is decreased. During routine p n i p  
weaning. flows are tlecreased in increments of 0.5 L/inin 
at 12- to 24-hour interpals. For a more rapid weaning, 
incremental decreases in f l c ~ ~  ihonld be no closer than 
30 minutes apart. The lowest flow that a patient is taken 
to during attemptetl weaning should he 2.0 Lhnin. The 
RV4D pump flow should he retlucetl hefore retlucing 
the LVA4L) flow. When flows are decreased lrelow 3 I h i n .  
the ACT should be increased to 300 seconds. With 
successful weaning. the VAD flow ratei should he 
returned to a level greater than 3 Lhnin, antl the patient 
should he returned to the operating room for tlecannu- 
lation. 
For clecannulation, the device in the better-recovered 
ventricle is explanted first. If both ventricles appear 
fully recovered, the RVA4D is removed first. During this 
process, the atrial cannula is clamped first. After three 
to four beats of the pimp,  allowing infusion of 200 to 
300 mL of pump blood, the device is turned off. 4 
vascular clamp is then applied distally to the Hemash- 
ield graft of the arterial cannula. The aorta and the 
pulmonary artery are not clamped. With the patient 
placed in a steep Trendelenburg position, and with a 
Valsalva maneuver produced by the anesthesiologist, 
the atrial cannula is removed and up to 100 mL of brisk 
blood loss is allowed from the atriotomy in order to 
evacuate any pannus that formed around the cannula. 
The Hemashield graft of the arterial cannula is then 
transected and evacuated of blood. The free edge is 
rolled upon itself, and final closure is performed with a 
two-layer running 4-0 polypropylene stitch over the 
rolletl tdpt.. Iltel-nati\ e l j?  a \awular stapling tie\ ice 
('an I)e applied a c r m s  tlie distal cuff of tlie arterial 
cannula instead of using the (~lanil)-an&ww tec~linicpe. 
In patients iintlergoing orthotopic cardiac transplanta- 
tion after Id\ AD placement. .cze clamp the cannulae. hut 
W Y  do not remope them until tlie recipient c~artliec~tonij 
is completed. This a l l o ~ s  o~wii ex1)os~ire of the atrial 
rhainhers ant1 direct r~1110~al (tf an) remaining pannus. 
The mediastinum is then t.vacuatrd and irrigated w i t h  
antibiotic solution. Debritlement of tlie strrnal edges 
antl sternal incision site is performed as neetletl. Pa- 
tency of niediastinal drains is then assured. The ster- 
num antl skin are then closed in the usual fashion. 
Survival to decannulation and subsecpent discharge 
from the hospital is strongly affected b y  patient selec- 
tion. Patients falling outside of the recommended crite- 
ria have chances of discharge as low as 8% to 14%.'.18 
Only 7% of patients placed 011 ventricular assist after 
cardiac arrest in the FDA-approved study survived to 
hospital discharge.2 The highest survival chances are 
found when the BVS 5000 is used as a briclge-to- 
transplantation, with reports of 72% to 75% survival 
for this indication, which is currently off label.".'9 For 
patients treated with ventricular failure without intent 
of the BVS 5000 as a bridge-to-transplantation, survival 
to discharge (Fig 11) is on the order of 25% to 70%.2.17-'9 
Enough emphasis cannot be placed on the importance 
of expeditious decision for device implantation because 
it avoids excessive inotrope use, end-organ damage, and 
initiation of futile device insertion. 
on 
"" I n = 28 
P-Card C-myo FailedTx AM1 Myocard Other 
Indication 
("/.) of total 
(64%) (lso/o) (9%) (6%) (2%) (4%) 
Fig 11. Survival to discharge for each patient category (n = 1,320). 
,4MI, amte myocardial infarction: C-myo, cardiomyoyathy; Myocard. 
myocarditis; P-card, postcardiotomy; Tx. transplantation. (From the 
ABIOMED BVS 5000 worldwide t1atal)ase as of May 1999.1 
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